Drugs / DC-CIK cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03190811 | Sep 2016 → Dec 2022 | neoplasm | Capital Medical University | Completed | No outcome recorded |
| Phase 1/2 | NCT02425735 | Apr 2015 → Jun 2016 | hepatocellular carcinoma | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC-CIK cells | “cultured DC-CIK cells for 10-14 days” NCT03190811 ↗ |
| Modality | Cell therapy | “After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as an immunotherapy treatment.” NCT02425735 ↗ |
| Route | Intravenous | “Cells were infused back to the patients in 3 times via intravenous infusion” NCT03190811 ↗ |